For decades, the search for new cancer drugs has returned to the same well. The most potent cytotoxic agents, the ones that can be delivered by antibody-drug conjugates (ADCs) to kill tumor cells, are often variations on a handful of known chemical themes. This creates a problem of diminishing returns and, eventually, resistance. Hexagon Bio, a Menlo Park biotech founded in 2016, is trying to dig a new well entirely. Its bet is that the next generation of ADC payloads, and other small-molecule medicines, are already encoded in the genomes of fungi and other microbes, waiting for a computational map to find them.
A computational wedge into natural products
The company's platform is a modern, systematic reboot of natural product drug discovery. Instead of culturing microbes in a lab and screening their secretions for activity, Hexagon starts with DNA. Its team sequences and analyzes the genomes of thousands of fungi and bacteria, using computational tools to predict which genetic clusters are likely to produce novel, drug-like small molecules called secondary metabolites [Hexagon Bio, September 2020]. The goal is to connect these genomic blueprints directly to potential protein targets in human disease, creating a proprietary database of nature's chemical repertoire [Hexagon Bio].
This genomic-first approach is the company's core wedge. It aims to access a chemical space that is both vast and evolutionarily refined for biological activity, but which has been largely inaccessible to traditional methods. The initial focus is squarely on oncology, specifically on discovering novel payloads for ADCs. These are the toxic warheads attached to antibodies that home in on cancer cells. Hexagon's thesis is that its platform can find payloads with new mechanisms of action, potentially overcoming resistance to current therapies and expanding the range of cancers treatable with ADCs [Hexagon Bio, February 2023].
The team translating data to drugs
The founding team brings together the distinct disciplines required to make this bet. CEO Maureen Hillenmeyer previously directed the Genomes to Natural Products program at Stanford, a role that sits at the exact intersection of genomics and drug discovery. Co-founder Brian Naughton was a founding scientist at 23andMe, bringing experience in building large-scale genetic datasets for human health [Forbes, June 2024]. Colin Harvey, a co-founder and Head of Platform, leads the synthetic biology and fungal genetics work, while academic co-founder Yi Tang, a professor at UCLA, provides deep expertise in natural product chemistry and biosynthesis [Hexagon Bio].
Recent leadership moves signal a shift from pure platform discovery toward clinical development. The company promoted Tara Arvedson from SVP of Research to Chief Scientific Officer, and formed a clinical advisory board with experts in ADC pharmacology and bioanalysis [Yahoo Finance]. Job postings for contract roles in bioconjugation and medicinal chemistry further indicate the company is building out the hands-on capabilities to turn its computational hits into drug candidates [Greenhouse, May 2026].
Fueling the platform with venture capital
Hexagon has raised significant capital to fund its ambitious, long-term discovery work. Since 2020, the company has closed three major rounds, bringing its total disclosed funding to over $185 million.
2020 Series A | 47 | M USD
2021 Financing | 61 | M USD
2023 Series B | 77.3 | M USD
The investor roster is a who's who of life sciences and tech crossover funds. The Column Group led the Series A, with Nextech Invest leading a $61 million round in 2021 that brought in SoftBank and Casdin Capital [Fierce Biotech, September 2021]. The $77.3 million Series B closed in February 2023, though the lead investor was not disclosed [Hexagon Bio, February 2023]. This level of backing suggests strong conviction in both the platform's potential and the experienced team executing the vision.
The competitive and clinical landscape
Hexagon is not alone in seeking to modernize natural product discovery. Competitors like LifeMine Therapeutics are also applying genomic and computational approaches to mine fungi for new medicines [BioPharma Dive]. The field remains early, with neither company yet reporting candidates in human clinical trials. The race will be won by who can most efficiently translate genomic predictions into validated, novel drug candidates with clear therapeutic advantages.
The risks for Hexagon are those inherent to any high-throughput discovery platform.
- The hit-to-lead gap. Computational prediction of a novel molecule is only the first step. The molecule must be produced, tested, and optimized for drug-like properties, a process with a high historical attrition rate.
- Payload differentiation. The bar for a new ADC payload is exceptionally high. It must demonstrate superior potency, a novel mechanism, or a better safety profile than established agents like auristatins or camptothecins to justify the development cost.
- Platform validation. The ultimate proof will be a pipeline. The company's platform must move beyond being a discovery engine to consistently generate candidates that advance toward the clinic.
Hexagon's answer to these challenges lies in its integrated approach. By combining genomics, data science, fungal genetics, and medicinal chemistry under one roof, it aims to close the loop between prediction and production faster than traditional outsourcing models allow. Its partnership with Corteva Agriscience on a joint venture for nature-inspired solutions, while in agriculture, also demonstrates an ability to deploy its platform for applied discovery [Hexagon Bio].
The patient population and the path forward
For patients with solid tumors, particularly those where current ADC therapies have failed or are ineffective, Hexagon's work represents a long-term hope for more targeted options. The company is targeting the disease state of advanced, treatment-resistant cancers, a population in desperate need of new therapeutic mechanisms.
The current standard of care for many of these patients involves chemotherapy regimens with broad toxicity or later-line targeted therapies with limited durability. ADCs have changed the landscape for some cancers, but their utility is constrained by the payloads available. Finding a new, potent payload with a different way of killing cancer cells could, in theory, restart the clock for ADC therapy across multiple tumor types.
The next twelve months will be critical for Hexagon to transition from platform to pipeline. Key milestones to watch include the nomination of a lead ADC candidate for preclinical development, the publication of peer-reviewed data validating its discovery approach, and potentially the announcement of a pharmaceutical partnership to co-develop a payload. With its funding runway and specialized team, Hexagon is positioned to test whether the next breakthrough cancer drug is written in the DNA of a fungus.
Sources
- [Hexagon Bio, September 2020] Hexagon Bio Closes $47 Million in Series A Financing | https://www.hexagonbio.com/series-a/
- [Hexagon Bio, February 2023] Hexagon Bio Raises $77.3 Million Series B Financing | https://www.hexagonbio.com/hexagon-bio-raises-77-3-million-series-b-financing-and-strengthens-leadership-to-expand-novel-computational-discovery-platform-and-advance-microbial-genome-derived-small-molecules/
- [Fierce Biotech, September 2021] Fungi funding: Hexagon Bio snags $61M | https://www.fiercebiotech.com/biotech/fungi-funding-hexagon-bio-snags-61m-to-test-drugs-from-fungi-for-cancer-infectious-diseases
- [Forbes, June 2024] 23andHim: The Untold Story Of 23andMe’s Third Co-Founder | https://www.forbes.com/sites/heatherwishartsmith/2024/06/25/23andhim-the-untold-story-of-23andmes-third-co-founder/
- [Yahoo Finance] Hexagon Bio announces formation of clinical advisory board | https://finance.yahoo.com/healthcare/articles/hexagon-bio-announces-formation-clinical-120000473.html
- [Greenhouse, May 2026] Associate Scientist/Scientist I, Bioconjugation, 1-Year Contract Position | https://job-boards.greenhouse.io/hexagonbio/jobs/7754191003
- [Hexagon Bio] Joint venture with Corteva | https://www.hexagonbio.com/news/